Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Significance: Alzheimer's disease (AD) is the most common cause of dementia in the elderly. AD is currently ranked as the sixth leading cause of death, but some sources put it as third, after heart disease and cancer. Currently, there are no effective therapeutic approaches to treat or slow the progression of chronic neurodegeneration. In addition to the accumulation of amyloid-β (Aβ) and tau, AD patients show progressive neuronal loss and neuronal death, also high oxidative stress that correlates with abnormal levels or overload of brain metals. Recent Advances: Several promising compounds targeting oxidative stress, redox metals, and neuronal death are under preclinical or clinical evaluation as an alternative or complementary therapeutic strategy in mild cognitive impairment and AD. Here, we present a general analysis and overview, discuss limitations, and suggest potential directions for these treatments for AD and related dementia. Critical Issues: Most of the disease-modifying therapeutic strategies for AD under evaluation in clinical trials have focused on components of the amyloid cascade, including antibodies to reduce levels of Aβ and tau, as well as inhibitors of secretases. Unfortunately, several of the amyloid-focused therapeutics have failed the clinical outcomes or presented side effects, and numerous clinical trials of compounds have been halted, reducing realistic options for the development of effective AD treatments. Future Directions: The focus of research on AD and related dementias is shifting to alternative or innovative areas, such as ApoE, lipids, synapses, oxidative stress, cell death mechanisms, neuroimmunology, and neuroinflammation, as well as brain metabolism and bioenergetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., Roberts, M. A., Tong, B., Maimone, T. J., Zoncu, R., et al. (2019) · Nature · doi:10.1038/s41586-019-1705-2 · Cited by 3,703
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · cited 2×
“The brain requires a high amount of energy in the form of ATP, but in MCI and AD, glucose metabolism is significantly impaired contributing to oxidative damage (18).”
Background2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 1×
“The imbalance of zinc in the brain could be related to the interaction of Zn with Ab aggregates (17), but contradictory results indicate that zinc modulates the nucleation of Ab retarding its aggregation (1).”
ResultSeiler, A., Schneider, M., Förster, H., Roth, S., Wirth, E. K., Culmsee, C., Plesnila, N., Kremmer, E., Rådmark, O., Wurst, W., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.005 · Cited by 1,470
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“Preclinical studies with transgenic AD mice showed a 49% reduction in Ab deposition after a 9-week course of clioquinol treatment and benefits in memory (25, 73).”
BackgroundImpact of intermittent fasting on health and disease processes
Mattson, M. P., Longo, V. D., & Harvie, M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.005 · Cited by 1,187 · cited 2×
“Intermittent fasting is an eating pattern in which individuals go over extended periods (usually 16–48 h) with little or no food intake followed by a period of normal food intake (113).”
BackgroundMediterranean diet and risk for Alzheimer's disease
Scarmeas, N., Stern, Y., Tang, M., Mayeux, R., & Luchsinger, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20854 · Cited by 1,103
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“A phase II trial with 36 subjects (125–375 mg twice daily, 36 weeks) showed tolerability, reduction in Ab, no effect in cognition, and no effect in plasma copper levels (143).”
BackgroundZhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R. G., Zhang, S., Abdelmohsen, K., Bohr, V. A., Misra Sen, J., Gorospe, M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0372-9 · Cited by 977 · cited 1×
“Analysis of the brain of AD patients and AD mice exhibited senescence-like phenotype in oligodendrocyte progenitor cells, with overexpression of p21/CDKN1A, p16/ INK4/CDKN2A, and detection of senescence-associated bgalactosidase (190).”
BackgroundHambright, W. S., Fonseca, R. S., Chen, L., Na, R., & Ran, Q. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.021 · Cited by 851
Lipid composition of the normal human brain: gray matter, white matter, and myelin
O'Brien, J. S., & Sampson, E. L. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39619-x · Cited by 848
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., et al. (2019) · Science · doi:10.1126/science.aav2546 · Cited by 813 · cited 1×
“In particular, chronic sleep deprivation increases Ab plaques and may promote tau accumulation (80).”
BackgroundIntranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699
Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Tau protein aggregation is associated with cellular senescence in the brain
Musi, N., Valentine, J. M., Sickora, K. R., Baeuerle, E., Thompson, C. S., Shen, Q., & Orr, M. E. (2018) · Aging Cell · doi:10.1111/acel.12840 · Cited by 595
Oxytosis: a novel form of programmed cell death
Shirlee Tan, B. S. P., David Schubert, B. S. P., & Pamela Maher, B. S. P. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394741 · Cited by 522
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Sultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.85 · Cited by 377
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer’s Disease
Reddy, P. H., Manczak, M., Yin, X., Grady, M. C., Mitchell, A., Tonk, S., Kuruva, C. S., Bhatti, J. S., Kandimalla, R., Vijayan, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170512 · Cited by 354
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 1×
“A pilot study with 80 patients with MCI tested 1000 mg metformin twice per day for 12 months, showing differences in ADAS-Cog but no significant differences in memory, glucose uptake PET, or plasma Ab (106).”
MethodVitamin C, Aging and Alzheimer’s Disease
Monacelli, F., Acquarone, E., Giannotti, C., Borghi, R., & Nencioni, A. (2017) · Nutrients · doi:10.3390/nu9070670 · Cited by 243 · cited 1×
“Ascorbic acid supplementation showed neuroprotective properties, reducing free radicals and neuroinflammation, also iron chelation and Ab reduction (118).”
BackgroundGeldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Association of Lithium in Drinking Water With the Incidence of Dementia
Kessing, L. V., Gerds, T. A., Knudsen, N. N., Jørgensen, L. F., Kristiansen, S. M., Voutchkova, D., Ernstsen, V., Schullehner, J., Hansen, B., Andersen, P. K., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2362 · Cited by 213
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193 · cited 1×
“Here, 511 subjects received 8 mg/day for 78 weeks, indicating that the compound was safe and well tolerated, but unfortunately without benefits in cognitive decline (99).”
BackgroundKarstens, A. J., Tussing-Humphreys, L., Zhan, L., Rajendran, N., Cohen, J., Dion, C., Zhou, X. J., & Lamar, M. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy275 · Cited by 136
Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121 · cited 1×
“A reduction in calories is linked with an extended lifespan, slowdown of aging, improved memory, and reduction of AD progression (170).”
BackgroundDementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E
Fillenbaum, G. G., Kuchibhatla, M. N., Hanlon, J. T., Artz, M. B., Pieper, C. F., Schmader, K. E., Dysken, M. W., & Gray, S. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g280 · Cited by 113 · cited 1×
“A longitudinal study of 600 elderly patients reported that around 8% of the subjects used vitamins C and/or E (normal dose or high dose), but the vitamins showed no correlation to reduce the time to develop dementia (52).”
BackgroundPioglitazone for the treatment of Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1265504 · Cited by 106 · cited 1×
“Phase II trial NCT00982202 with 29 nondiabetic AD subjects was shown to be safe and well tolerated with a dose of 45 mg/day (58, 64).”
BackgroundAMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell, A. S., Gonzales, C., Williams, J., Witte, M. M., Mohs, R. C., & Sperling, R. (2007) · Neurology · doi:10.1212/01.wnl.0000260240.46070.7c · Cited by 89 · cited 1×
“0 mg thereafter for 8-weeks) showed no significant changes in cognition, and the majority of patients showed mild adverse effects (22).”
BackgroundConcurrent Administration of Coenzyme Q10 and α-Tocopherol Improves Learning in Aged Mice
Mcdonald, S. R., S. Sohal, R., & Forster, M. J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.11.014 · Cited by 77
Wang, C.-Y., Xie, J.-W., Xu, Y., Wang, T., Cai, J.-H., Wang, X., Zhao, B.-L., An, L., & Wang, Z.-Y. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5158 · Cited by 66 · cited 1×
“In APP/PS1 mice, a 3-month treatment of TETA reduced Ab deposition and synapse loss (29, 175).”
BackgroundPickart, L., Vasquez-Soltero, J., & Margolina, A. (2017) · Brain Sciences · doi:10.3390/brainsci7020020 · Cited by 51
Shetty, R. A., Forster, M. J., & Sumien, N. (2013) · AGE · doi:10.1007/s11357-012-9484-9 · Cited by 47
Sha, S. J., Miller, Z. A., Min, S., Zhou, Y., Brown, J., Mitic, L. L., Karydas, A., Koestler, M., Tsai, R., Corbetta‐Rastelli, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.002 · Cited by 36 · cited 1×
“A phase I trial showed no benefits or effects on secondary outcomes (CSF Ab, tau, and p-tau) after an 8-week treatment of nimodipine (153).”
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
The Role of Selenium in Pathologies: An Updated Review
Barchielli, G., Capperucci, A., & Tanini, D. (2022) · Antioxidants · doi:10.3390/antiox11020251 · Cited by 371
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Aborode, A. T., Pustake, M., Awuah, W. A., Alwerdani, M., Shah, P., Yarlagadda, R., Ahmad, S., Silva Correia, I. F., Chandra, A., Nansubuga, E. P., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7934442 · Cited by 124
The mechanisms of ferroptosis and its role in alzheimer’s disease
Ma, H., Dong, Y., Chu, Y., Guo, Y., & Li, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965064 · Cited by 115
Metadata
- Authors
- Plascencia-Villa, G., & Perry, G.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2021-03-10
- Volume
- 34
- Issue
- 8
- Pages
- 591-610
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W3029056655
- Cited by
- 188
- References
- 40
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.